Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Roche

Pharma Q3 Results Preview: Novartis, Lilly, Amgen, GSK

There's optimism around Novartis as it heads into its final quarter with Joe Jimenez in charge, while Lilly faces impending headwinds, GSK will be touting Shingrix for future growth as vaccines growth tempers, and Amgen treads a complicated path through the biosimilar landscape.

Sales & Earnings Business Strategies

Deal Watch: Syndax Gets Former Vitae Leukemia Program From Allergan

Cancer-focused biotech obtains preclinical program aimed at leukemia subset involving chromosomal rearrangements. Merck acquires an interest in KalVista and rights to its diabetic macular edema candidate, while Arcturus partners with Janssen in hepatitis B.

Deals M & A

England’s NICE Takes Tough Stance On Opdivo; No Relief from Cancer Drugs Fund

HTA body NICE has rejected in draft guidance the use in the NHS in England of Opdivo (nivolumab) in bladder cancer. Also, the BMS product is unlikely to gain reimbursement from the Cancer Drugs Fund for the indication because further clinical trials in bladder cancer are not ongoing. Similar issues affect the initial rejection by NICE of lenvatinib and sorafenib in advanced metastatic differentiated thyroid cancer patients.

Health Technology Assessment Pricing Strategies

Scrip Asks… What's The Current Climate For Deal-Making? (Part 2)

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.

Business Strategies M & A
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register